secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2025-12-03T23:59:59+00:00
Accession:  0001628280-25-055083
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen appoints Nick Tressler as CFO effective Dec 1, 2025
------------------------------------------------------------

- Nick Tressler named CFO & Treasurer, effective Dec 1, 2025; succeeds Shawn Singh as interim PFO.
- Starting annual base salary of $450,000; signing bonus of $50,000; target cash bonus of 45% of base.
- Granted inducement option for 150,000 shares at $4.43 per share; vests over 4 years with 1-yr cliff.
- Tressler brings 20+ years life sciences finance experience; most recently CFO at DYNEX Technologies.
- Shawn Singh will no longer serve as interim principal financial and accounting officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828025055083/0001628280-25-055083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828025055083/vtgn-20251128.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-055083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer